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The epidemiological and programmatic implications of inclusivity of HIV-positive males in
voluntary medical male circumcision (VMMC) programs are uncertain. We modeled these
implications using Zambia as an illustrative example.
Methods and Findings
We used the Age-Structured Mathematical (ASM) model to evaluate, over an intermediate
horizon (2010–2025), the effectiveness (number of VMMCs needed to avert one HIV infec-
tion) of VMMC scale-up scenarios with varying proportions of HIV-positive males. The
model was calibrated by fitting to HIV prevalence time trend data from 1990 to 2014. We
assumed that inclusivity of HIV positive males may benefit VMMC programs by increasing
VMMC uptake among higher risk males, or by circumcision reducing HIV male-to-female
transmission risk. All analyses were generated assuming no further antiretroviral therapy
(ART) scale-up.
The number of VMMCs needed to avert one HIV infection was projected to increase from
12.2 VMMCs per HIV infection averted, in a program that circumcises only HIV-negative
males, to 14.0, in a program that includes HIV-positive males. The proportion of HIV-positive
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males was based on their representation in the population (e.g. 12.6% of those circumcised
in 2010 would be HIV-positive based on HIV prevalence among males of 12.6% in 2010).
However, if a program that only reaches out to HIV-negative males is associated with 20%
lower uptake among higher-risk males, the effectiveness would be 13.2 VMMCs per infec-
tion averted. If improved inclusivity of HIV-positive males is associated with 20% higher
uptake among higher-risk males, the effectiveness would be 12.4. As the assumed VMMC
efficacy against male-to-female HIV transmission was increased from 0% to 20% and 46%,
the effectiveness of circumcising regardless of HIV status improved from 14.0 to 11.5 and
9.1, respectively. The reduction in the HIV incidence rate among females increased accord-
ingly, from 24.7% to 34.8% and 50.4%, respectively.
Conclusion
Improving inclusivity of males in VMMC programs regardless of HIV status increases
VMMC effectiveness, if there is moderate increase in VMMC uptake among higher-risk
males and/or if there is moderate efficacy for VMMC against male-to-female transmission.
In these circumstances, VMMC programs can reduce the HIV incidence rate in males by
nearly as much as expected by some ART programs, and additionally, females can benefit
from the intervention nearly as much as males.
Introduction
Randomized controlled trials (RCT) reported approximately 60% efficacy for male circumci-
sion against heterosexual HIV acquisition among males [1–3]. Current evidence suggests that
voluntary male medical circumcision (VMMC) is an effective, cost-effective, and cost-saving
HIV prevention intervention [4–10]. The World Health Organization (WHO) and the Joint
United Nations Programme on HIV/AIDS (UNAIDS) recommend VMMC as part of a com-
prehensive HIV prevention package in several countries in East and Southern Africa [11, 12].
WHO and UNAIDS recommend that HIV testing and counseling (HTC) be offered to all
clients presenting for VMMC, as part of the comprehensive package of HIV prevention ser-
vices [11]. While VMMC for HIV prevention purposes is not recommended for uncircum-
cised HIV-positive males, WHO and UNAIDS stipulate that HIV positive individuals
requesting VMMC should not be denied the service solely due to HIV status, to avoid stigma
[11]. To date, HTC acceptance rates have generally been high [11, 13]. This is a positive out-
come given that awareness of HIV status is an important component of HIV prevention [13,
14], and that HIV-positive males are linked to HIV care and treatment services [15]. At the
same time, though, qualitative analyses suggested that there is a risk that higher-risk HIV-neg-
ative males might forgo VMMC if they perceive that HTC is mandatory, for fear of an HIV-
positive diagnosis or that they will be identified as HIV-positive by their communities [16, 17].
A factor for policymakers to consider when determining whether VMMC recruitment
activities should include all males, regardless of HIV status/awareness, is the potential efficacy
of male circumcision against HIV transmission from a circumcised HIV-positive male to his
female sexual partners (male-to-female HIV transmission). The evidence is mixed on this effi-
cacy [18–25]. Females with circumcised partners have been found to have an equal [18, 22,
26], lower [21, 23, 27–29], or higher [18, 30, 31] risk of acquiring HIV than those with uncir-
cumcised partners. Two studies attempted to pool existing evidence on this effect [19, 20]. The
Implications of Circumcising HIV-Positive Males
PLOS ONE | DOI:10.1371/journal.pone.0170641 January 24, 2017 2 / 20
E. Njeuhmeli, study co-author, had a role in study
design and manuscript preparation.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: ART, antiretroviral therapy; ASM,
Age-Structured Mathematical; HTC, HIV testing
and counseling; RCT, Randomized controlled trial;
SSA, sub-Saharan Africa; UNAIDS, Joint United
Nations Programme on HIV/AIDS; VMMC,
voluntary medical male circumcision; WHO, World
Health Organization.
first study, a systematic review and meta-analysis in 2009, reported that male circumcision had
a 20% efficacy against male-to-female HIV transmission, but with no statistical significance
[19]. The second study, a meta-analysis in 2010, pooled the outcome of two quality measures
from two observational cohorts and reported a statistically significant 46% efficacy for male
circumcision [20].
The only RCT to directly test for a difference in HIV transmission risk to females based on
males’ circumcision status was stopped early, for futility [18]. The study demonstrated a statis-
tically insignificant increased risk of infection in females who resumed sex before the circum-
cision wounds of their partners had healed, in comparison with the HIV transmission risk of
females with uncircumcised partners and of females who did not resume sex before their part-
ners circumcision wounds had healed [18]. There is evidence that 4% to 31% of males—
including those identified as HIV-positive prior to VMMC—resume sex before their wounds
heal [25, 31–34]. If more than 30% of males resume sexual activity too soon, one model of the
impact suggests that there could be a net negative effect on their female partners within the
first year post-circumcision: that is, the intervention would generate more new infections
among females [34]. This model, however, only assessed the impact of VMMC on the HIV epi-
demic over one year and did not capture longer term impact. The model’s finding was also
generated assuming high relative risk of male-to-female HIV transmission during wound heal-
ing and a consistent coital frequency [34]. These two assumptions may be unrealistic, and lead
to an underestimation of the beneficial impact of VMMC and an overestimation of the nega-
tive impact on females. Regardless, this modeling study and other studies show that even in
the first year, early resumption of sex will not offset the overall epidemiological benefits of
VMMC programs [7, 8, 10, 20, 25, 34].
In this study, we used mathematical modeling to assess the epidemiological and some pro-
grammatic implications of including HIV-positive males in VMMC programs. The primary
outcome of interest was the effectiveness of VMMC as an HIV intervention, defined as the
number of VMMCs needed per HIV infection averted. The lower the number of VMMCs
required to avert one infection, the better the effectiveness of VMMC in that scenario. The sec-
ondary outcome of interest was the scale of reduction in the risk of HIV exposure, defined as
HIV incidence rate reduction. This measure was calculated by comparing the population-level
HIV incidence rate in the presence of the VMMC scale-up program with a counter-factual sce-
nario with no VMMC scale-up program.
The intervention’s impact on the HIV epidemic was evaluated in two time horizons: an
intermediate-term time horizon (2010–2025), and a long-term time horizon (2010–2035). We
mainly focused in our analyses on the intermediate time horizon, as the goal of the VMMC
program is to impact the HIV epidemic in the near to intermediate future [35].
Our analysis focused on Zambia as an illustrative example, with the purpose of assessing
the implications of including HIV-positive males in VMMC programs in countries with high
HIV prevalence and low circumcision rates. The VMMC program in Zambia aims to reduce
HIV incidence by circumcising 80% of 15–49 year old males between 2010 and 2017, for a
total of 1.95 million circumcisions [36]. While Zambia’s VMMC program does not exclude
HIV-positive males who meet the other eligibility requirements, about 99% of VMMC clients
to date have been HIV-negative males [37].
Methods
Modeling Approach
We used the Age-Structured Mathematical (ASM) model [38, 39] to address the research
questions of this study. Detailed description of the ASM model and parameterization, and
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description of the HIV epidemic in Zambia, can be found in S1 Text and Awad et al. [38].
Briefly, the ASM model is a population-level deterministic compartmental mathematical
model that describes the heterosexual transmission of HIV in a given population (S1 Fig).
Deterministic modelling is an appropriate choice to examine HIV dynamics and the effective-
ness of intervention programs at the national level for such large HIV epidemics. The model
consists of a set of coupled nonlinear differential equations that stratify the population into
compartments according to sex (males and females), circumcision status of males, age group,
sexual risk group, HIV status, and stage of HIV infection. Progression of HIV infection is
divided into three stages: acute, chronic, and advanced.
The model disaggregates the population into 20 age groups with each group representing a
five-year age band (0–4, 5–9, . . ., 95–99 year old). To account for heterogeneity in sexual risk
behavior, we incorporated six sexual risk groups in the population with increasing level of
sexual risk behavior [38]. The distribution of the population across the six risk groups was
informed by empirical data from sub-Saharan Africa (SSA) on the distribution of the number
of sexual partners over the past year [40–44]. Accordingly, the risk group in the model repre-
senting the general population (risk group 1) has the lowest risk of acquiring HIV in the study
population. The risk group representing key populations to the HIV epidemic such as female
sex workers and their male clients (risk group 6) has the highest risk of acquiring HIV [38].
The overall level of sexual risk behavior was assumed to vary during the HIV epidemic, as evi-
dence has shown substantial reductions in the risk of HIV exposure across SSA [45]. Further
details on sexual risk behavior parameterization and its time evolution can be found in S1
Text. Individuals of different risk and age groups interact according to mixing matrices that
describe sexual networking and incorporate both an assortative component (choosing partners
from within their risk or age group) and proportionate component (choosing partners with no
preferential bias based on the type of risk group or age group) mixing [38, 46, 47].
A proportion of males in the population of Zambia was assumed to be circumcised through
traditional circumcision, as per Demographic and Health Surveys data [48]. The efficacy of
VMMC against HIV acquisition among males was modeled as a proportional reduction in the
risk of HIV acquisition among circumcised males. The efficacy of VMMC against male-to-
female HIV transmission was modeled as a fractional reduction in the transmission probability
per coital act. Existing data and the postulated biological mechanisms of action do not suggest
differential effect of VMMC by HIV stage of infection (i.e. acute, chronic and advanced stages)
[19, 20]. Accordingly, we assumed that each of the efficacies of VMMC against HIV acquisi-
tion among males and against male-to-female HIV transmission is not stage dependent and
equal for all HIV stages. The model accommodates the possibility of risk compensation among
circumcised males following VMMC, but we assumed 0% risk compensation in our predic-
tions based on inconclusive empirical evidence to support increases in risk behavior [49–53].
Data Sources and Model Fitting
The model was parameterized using current epidemiological and natural history data from
SSA [38], as well as through model fitting for some of the parameters. HIV biological and
behavioral parameter values are described in Awad et al. [38]. The country-specific time series
of HIV prevalence data was obtained from UNAIDS estimates between 1990 and 2011 [54].
Baseline male circumcision prevalence, reflecting background non-VMMC program circum-
cisions in Zambia, was obtained from the Zambia Demographic and Health Survey 2007 [55].
Demographics such as total population size and future projections were obtained from the
database of the Population Division of the United Nations Department of Economic and
Social Affairs [56].
Implications of Circumcising HIV-Positive Males
PLOS ONE | DOI:10.1371/journal.pone.0170641 January 24, 2017 4 / 20
The model was fitted to HIV prevalence time series data in the years between 1990 and
2014, using a nonlinear least-square fitting method. The technique was implemented in
MATLAB version 2015a [57] using the Nelder-Mead simplex algorithm (fminsearch) as
described in Lagarias et al. [58].
VMMC Intervention Scenarios
In the modeled intervention scenarios, the scale-up of the VMMC program was assumed to
start in 2010, with a “catch-up” phase lasting seven years (to 2017) and a “sustainability” phase
lasting another eight years (to 2025). The catch-up phase focused on the 15–49 year old popu-
lation and ends by achieving 80% VMMC coverage in this age bracket. In the sustainability
phase, the attained coverage achieved during the catch-up phase was maintained by circumcis-
ing cohorts as they entered the 15–49 year old population. The model assumed scale-up of
VMMC at a fixed rate—that is, the likelihood of any male within the targeted population to be
circumcised was uniform. These VMMC intervention scenarios assume 80% VMMC coverage
among 15–49 year old males per the WHO/UNAIDS recommendation and as adopted by the
Government of Zambia [11, 12, 36]. VMMC coverage of 80% has been also adopted as the
baseline of choice across countries in SSA in the ongoing modeling efforts for assessing
VMMC program efficiency gains [38, 59]. The number of VMMCs needed to avert one HIV
infection (effectiveness) of the VMMC intervention program was evaluated over an intermedi-
ate period (2010–2025) and a long-term horizon (2010–2035). All analyses were produced
assuming no antiretroviral therapy (ART) scale-up.
Implications of including HIV-positive males. Three different VMMC program scenar-
ios were modeled. To allow for comparative analyses, VMMC scale-up was assumed identical
in these three scenarios, and as representative of actual scale-up as possible, apart from the
inclusion criteria of HIV-positive males.
In the first scenario, the VMMC program circumcised only HIV-negative males. In the sec-
ond scenario, the VMMC program circumcised both HIV-negative and HIV-positive males,
in line with program data for Zambia [37]. Accordingly, less than 1% of those circumcised in
this scenario were HIV-positive. In the third scenario, the VMMC program circumcised males
regardless of their HIV status (no differential targeting by HIV status), such that HIV-negative
and -positive males had an equal chance of being circumcised. Accordingly, 12.6% of those cir-
cumcised in 2010 in this scenario were HIV-positive, similar to HIV prevalence among males
of 12.6% in 2010. This fraction, however, changed in the simulations with the temporal evolu-
tion of HIV prevalence (S2 Fig). In the three scenarios, it was assumed that there was no effect
on higher-risk males accepting services (does not dissuade higher-risk HIV-negative and -pos-
itive males from accepting VMMC).
Uptake among higher-risk males due to VMMC implementation criteria. The inclu-
sivity of HIV-positive males in VMMC programs may affect the uptake of circumcision
among higher-risk HIV-negative males, as they may avoid going to a VMMC program due to
fear of being required to test for HIV, or learning their HIV status, or of testing positive for
HIV [16, 17, 60, 61]. Increased VMMC uptake among higher-risk males may reduce the
number of VMMCs needed to avert one HIV infection, since higher-risk males derive a
greater absolute reduction in HIV acquisition and transmission risk than do lower-risk males
[10, 38, 39]. For example, in our model application for Zambia, around 40% of HIV acquisi-
tions and more than 90% of HIV transmissions are occurring among or through the three
highest risk groups.
Against this background, we examined the impact of VMMC uptake among higher-risk
HIV-negative males under different assumptions. Given that there are no specific quantitative
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data on the risk behavior distribution of males seeking circumcision, we conducted the follow-
ing analyses:
• We modeled an intervention scenario in which we assessed the effectiveness of a VMMC
program including only HIV-negative males, but with 20% lower male circumcision uptake
among higher-risk males (the three highest risk groups in the model). The 20% lower uptake
scenario among higher risk males was based on consensus of expert opinion.
• We modeled an intervention scenario in which we assessed the effectiveness of a VMMC
program that includes HIV-positive males at a rate proportional to their representation in
the population (e.g. 12.6% of those circumcised in 2010 would be HIV-positive males based
on an HIV prevalence of 12.6% among males), but with 20% higher male circumcision
uptake among higher-risk males. The 20% higher uptake scenario among higher risk males
was based on consensus of expert opinion.
Efficacy of male circumcision against male-to-female HIV transmission. In our analy-
ses, we used three different levels of efficacy of male circumcision against male-to-female HIV
transmission:
1. No efficacy of male circumcision against male-to-female HIV transmission—i.e. 0%.
2. A 20% efficacy of male circumcision against male-to-female HIV transmission, as informed
by the Weiss et al. systematic review and meta-analysis [19]
3. A 46% efficacy of male circumcision against male-to-female HIV transmission, as informed
by the Hallett et al. meta-analysis of two quality measures [20]
We conducted a sensitivity analysis assessing the impact of higher HIV infectiousness
among circumcised males who resume sexual activity before the complete healing of their cir-
cumcision wounds [18, 31, 62]. We assumed a 3.5-fold increase in male-to-female HIV trans-
mission during the wound healing period—that is two to six weeks post circumcision—per
available evidence [18, 34].
Fig 1 summarizes all of the above-modeled intervention scenarios.
Uncertainty Analysis
Multivariate uncertainty analysis was conducted to specify the range of uncertainty in the
effectiveness of VMMC with respect to variations in the structural and biological parameters
of the model. The analysis was conducted using Monte Carlo sampling from uniform proba-
bility distributions (MATLAB algorithm: unifrnd) for the uncertainty in HIV natural history
and transmission parameters and behavioral parameters of the model, and by assuming an
uncertainty of 20% around the point estimates of all parameters. The varied parameters
included: HIV transmission probability per coital act, duration of each HIV stage, frequency
of coital acts per HIV stage, duration of partnership, degree of assortativeness, scale parameter
in the gamma distribution of the population across the risk groups, and exponent parameter
in the power-law function of the distribution of sexual-risk behavior (S2 Table). The uncer-
tainty range of ±20% in input parameters was informed by the range used in modeling litera-
ture [45, 63, 64]. Each set of new parameters was used to refit the HIV prevalence time series
data in Zambia and then assess the effectiveness of the VMMC program. We implemented 500
uncertainty runs for each modeled intervention scenario. The 500 runs were chosen as the
optimal number of uncertainty runs encompassing as much as possible of the parameter space
Implications of Circumcising HIV-Positive Males
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while maintaining computational feasibility. We derived the geometric mean effectiveness and
associated 95% uncertainty interval from the distribution of outcomes of the uncertainty runs.
Results
Implications of Including HIV-Positive Males
Fig 2 shows three modeled VMMC intervention scenarios that assess the implications of
including HIV-positive males in the VMMC program in Zambia. In these scenarios, no effi-
cacy of male circumcision against male-to-female HIV transmission was assumed. In the first
scenario, circumcising only HIV-negative males, the effectiveness was 12.2 VMMCs per HIV
infection averted. In the second scenario, circumcising in accord with current program data
(less than 1% of those circumcised are HIV-positive), the effectiveness was the same: 12.2
VMMCs per HIV infection averted. In the third scenario, circumcising males regardless of
their HIV status, the effectiveness was 14.0 VMMCs per HIV infection averted.
S3 Fig shows the range of uncertainty for the three modeled VMMC intervention scenarios
that assess the implications of including HIV-positive males in the VMMC program in
Fig 1. Diagram summarizing research questions and modeled intervention scenarios investigated in this study. * This fraction changes with the
temporal changes in HIV prevalence Effectiveness is defined as the number of VMMCs needed to avert one HIV infection. VMMC: Voluntary medical male
circumcision.
doi:10.1371/journal.pone.0170641.g001
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Zambia. In each uncertainty run, the relative difference in VMMC effectiveness across scenar-
ios was preserved confirming our results reported above.
Uptake among Higher-Risk Males Due to VMMC Implementation Criteria
Fig 3 shows the impact on Zambia’s VMMC program of excluding HIV-positive males, if the
exclusion was associated with lower uptake of the VMMC intervention among higher-risk
males. Here, no efficacy of male circumcision against male-to-female HIV transmission was
assumed. Circumcising only HIV-negative males, the effectiveness was 12.2 VMMCs per HIV
infection averted. In the scenario in which the VMMC program excluded HIV-positive males,
but with 20% lower uptake among higher-risk males, the effectiveness was 13.2 VMMCs per
HIV infection averted.
Fig 3 further shows the impact on Zambia’s VMMC program of including HIV-positive
males, if the inclusion was associated with higher uptake of the VMMC intervention among
higher-risk males. Circumcising regardless of HIV status, the effectiveness was 14.0 VMMCs
per HIV infection averted. In the scenario in which the VMMC program included HIV-posi-
tive males, but with 20% higher uptake among higher-risk males, the effectiveness was 12.4
VMMCs per HIV infection averted.
Efficacy of Male Circumcision against Male-to-Female HIV Transmission
Fig 4 shows the impact of assuming an efficacy for male circumcision against male-to-female
HIV transmission. Assuming 20% efficacy, the effectiveness was 11.5 VMMCs per HIV infec-
tion averted, regardless of scenario: circumcising only HIV-negative males, circumcising
Fig 2. Impact of excluding or including HIV-positive males in the VMMC program in Zambia. The figure shows the effectiveness of the
VMMC program including i) only HIV-negative males, ii) HIV-positive males as per current program data, and iii) proportion of HIV-positive
males, based on their representation in the population. No efficacy of male circumcision against male-to-female HIV transmission was
assumed. Effectiveness is defined as the number of VMMCs needed to avert one HIV infection.
doi:10.1371/journal.pone.0170641.g002
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males in accord with current program data, or circumcising males regardless of their HIV sta-
tus (Fig 4A). By incorporating an efficacy of VMMC against HIV acquisition among circum-
cised HIV negative males and a 20% efficacy of VMMC against male-to-female HIV
transmission among circumcised HIV positive males, the model produced (after rounding)
similar quantitative results in the three scenarios regardless of inclusion criteria of HIV-posi-
tive males.
Fig 4B shows the effectiveness of the VMMC program at different male circumcision effi-
cacy levels of 0%, 20%, and 46%. In these scenarios, males were circumcised regardless of their
HIV status. At 0% efficacy, the effectiveness was 14.0 VMMCs per HIV infection averted. At
20% efficacy, the effectiveness was 11.5 VMMCs per HIV infection averted. At 46% efficacy,
the effectiveness was 9.1 VMMCs per HIV infection averted.
S4 Fig shows the sensitivity analysis assessing the impact of higher HIV infectiousness
among circumcised males who resume sexual activity before the complete healing of their
circumcision wound. The higher HIV infectiousness marginally affected both VMMC effec-
tiveness (comparing S4 Fig to Fig 2) and the relative differences in VMMC effectiveness (com-
paring the three scenarios in S4 Fig to each other).
The Impact of Male Circumcision Efficacy Levels on the HIV Incidence
Rate
Fig 5 shows the impact on the HIV incidence rate of different male circumcision efficacy levels
against male-to-female HIV transmission. In these scenarios, males were circumcised regard-
less of their HIV status, assuming no effect on VMMC uptake among higher-risk HIV-
Fig 3. Effectiveness of the VMMC program in Zambia at different uptake levels among higher-risk males. The figure shows the effectiveness of
the VMMC program including i) only HIV-negative males, ii) only HIV-negative males, but with 20% lower uptake of VMMC among higher-risk males, iii)
proportion of HIV-positive males, based on their representation in the population, but with 20% higher uptake of VMMC among higher-risk males, and
iv) proportion of HIV-positive males, based on their representation in the population. No efficacy of male circumcision against male-to-female HIV
transmission was assumed. Effectiveness is defined as the number of VMMCs needed to avert one HIV infection.
doi:10.1371/journal.pone.0170641.g003
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Fig 4. Effectiveness of the VMMC program in Zambia assuming different male circumcision efficacy levels against male-to-
female HIV transmission. A) The panel shows the effectiveness of the VMMC program, assuming 20% efficacy for male
circumcision against male-to-female HIV transmission, including i) only HIV-negative males, ii) HIV-positive males as per current
program data, and iii) proportion of HIV-positive males, based on their representation in the population. B) The panel shows the
effectiveness of the VMMC program including a proportion of HIV-positive males, based on their representation in the population, but
assuming i) 0% efficacy, ii) 20% efficacy, and iii) 46% efficacy against male-to-female HIV transmission. Effectiveness is defined as
the number of VMMCs needed to avert one HIV infection.
doi:10.1371/journal.pone.0170641.g004
Implications of Circumcising HIV-Positive Males
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Fig 5. Impact of different male circumcision efficacy levels, against male-to-female HIV transmission, on HIV incidence
rate reduction in Zambia. Incidence rate reduction in A) the female population and in B) the male population with the VMMC
program including a proportion of HIV-positive males, based on their representation in the population. The panels assume i) 0%
efficacy, ii) 20% efficacy, and iii) 46% efficacy of male circumcision against male-to-female HIV transmission.
doi:10.1371/journal.pone.0170641.g005
Implications of Circumcising HIV-Positive Males
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negative males. At 0% efficacy, the incidence rate reduction among the female population in
Zambia was 24.7% in the year 2025 (Fig 5A). At 20% efficacy, the incidence rate reduction was
34.8% that same year, and at 46% efficacy, the incidence rate reduction was 50.4% (Fig 5A).
At 0% efficacy, the incidence rate reduction among the male population in Zambia was
45.2% in the year 2025 (Fig 5B). At 20% efficacy, the incidence rate reduction was 49.2% that
same year, and at 46% efficacy, the incidence rate reduction was 56.4% (Fig 5B).
Table 1 summarizes the results of all of the above-modeled intervention scenarios evaluated
over an intermediate horizon (2010–2025), while S2 Table summarizes the results of all of the
above-modeled intervention scenarios evaluated over a long-term horizon (2010–2035).
Discussion
Epidemiological and some programmatic implications of including HIV-positive males in
VMMC programs were examined in this study using mathematical modeling (the ASM
model). The primary finding is that including HIV-positive males in VMMC programs is
Table 1. Effectiveness of the VMMC program in Zambia under different VMMC intervention scenarios.
Modeled VMMC intervention scenario Assumed efficacy of male circumcision
against male-to-female HIV transmission
Effectiveness (number of
VMMCs per HIV infection
averted)
Implications of including HIV-positive males (Fig 2)
A VMMC program including only HIV-negative males 0% 12.2
Current VMMC program (less than 1% of those circumcised are HIV-
positive)
0% 12.2
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
0% 14.0
Uptake among higher-risk males due to VMMC implementation criteria (Fig 3)
A VMMC program including only HIV-negative males 0% 12.2
A VMMC program including only HIV-negative males, but with 20%
lower uptake among higher-risk males
0% 13.2
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
0% 14.0
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*, but with 20% higher uptake
among higher-risk males
0% 12.4
Efficacy of male circumcision against male-to-female HIV transmission (Fig 4)
Fig 4A
A VMMC program including only HIV-negative males 20% 11.5
Current VMMC program (less than 1% of those circumcised are HIV-
positive)
20% 11.5
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
20% 11.5
Fig 4B
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
0% 14.0
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
20% 11.5
A VMMC program including a proportion of HIV-positive males, based
on their representation in the population*
46% 9.1
Effectiveness is defined as the number of VMMCs needed to avert one HIV infection. VMMC: Voluntary medical male circumcision.
* For instance, 12.6% of those circumcised in 2010 were HIV-positive based on an HIV prevalence of 12.6% among males in 2010. This percentage
changes with the temporal changes in HIV prevalence in Zambia.
doi:10.1371/journal.pone.0170641.t001
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unlikely to substantially undermine the efficiency of VMMC programs to achieve the desired
epidemic impact. On the contrary, implementing VMMCs regardless of HIV status may
improve the effectiveness of VMMC programs, by reducing the number of VMMCs needed to
avert one HIV infection, depending on the assumptions.
Of all of the scenarios considered, only the one that assumed 0% protection against male-
to-female transmission and no effect on uptake among higher-risk males resulted in lower
effectiveness by including HIV-positive males. Although a VMMC program in Zambia that
reaches only HIV-negative males may reduce the number of VMMCs per HIV infection
averted by up to 15% (Fig 2), in reality, this is not likely to occur. Though not yet validated
with concrete data, we believe that programs that inadvertently reach only HIV-negative males
may be discouraging higher-risk males from presenting for VMMC due to concerns about
mandatory HTC and knowledge or disclosure of their HIV status. Decreased demand for ser-
vices among these males could lower the effectiveness of the VMMC programs. If VMMC
uptake among higher-risk HIV-negative males is reduced by as little as 20%, the number of
VMMCs needed to avert one HIV infection would increase by 8% (Fig 3). If VMMC uptake
among higher-risk HIV-negative males is reduced by more than 20%, the number of VMMCs
needed to avert one HIV infection would increase even more.
If, on the other hand, improved inclusivity of HIV-positive males increases VMMC uptake
among higher-risk males, the increased effectiveness will likely make inclusion of HIV-positive
males more beneficial than exclusion. For example, if VMMC uptake among higher-risk males
is increased by as little as 20% (in a program that includes HIV-positive males), the number of
VMMCs needed to avert one HIV infection will be similar to that of a program that only cir-
cumcises HIV-negative males (Fig 3). If VMMC uptake among higher-risk males is increased
by more than 20%, the number of VMMCs needed to avert one HIV infection will decrease
even more.
These results are not surprising in light of recent findings showing that the number of
VMMCs needed to avert one HIV infection is highly sensitive to risk-group targeting [38].
Higher uptake among higher-risk males leads to a greater absolute reduction in risk and
greater epidemiological impact in terms of averted HIV infections. This finding, we believe,
hints indirectly to the importance of reducing HIV stigma and avoiding lower uptake of
VMMC among high-risk males. We believe that recruitment messages should frame VMMC
more broadly as a sexual and reproductive health service, reinforce that HTC services are
offered but not required, and ensure health care workers are providing VMMC to clinically eli-
gible males regardless of HIV status and willingness to test for HIV.
Furthermore, if male circumcision has any efficacy against male-to-female HIV transmis-
sion—an effect for which there is empirical evidence [19, 20, 65]—the number of VMMCs
needed to avert one HIV infection will be further reduced by inclusion of HIV-positive males.
If the efficacy of circumcision against male-to-female HIV transmission is as little as 20%, the
number of VMMCs needed per HIV infection averted, in a VMMC program that circumcises
HIV-positive males at a rate proportional to their representation in the population, would be
reduced by 22% (Fig 4A). If the efficacy is as high as 46%, the number of VMMCs needed per
HIV infection averted would be reduced by 55% (Fig 4B).
The combination of a moderate increase in VMMC uptake among higher-risk males (i.e.
20%), and a moderate efficacy of male circumcision against male-to-female HIV transmission
(i.e. 20%), supports program efficiency of including HIV-positive males in VMMC programs.
Inclusion of HIV-positive males in VMMC programs would reduce HIV incidence rate by as
much as some lifelong ART programs achieve. ART coverage in some programs can reduce
HIV incidence rate by as much as 50% [66], while our results show that VMMC (a one-time
intervention) can reduce HIV incidence rate by as much as 42%.
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The evidence of male circumcision efficacy against male-to-female HIV transmission has
an important implication: VMMC programs will benefit females nearly as much as males. If
VMMC’s efficacy against male-to-female HIV transmission is 46%, as a recent meta-analysis
found [20], the incidence rate reduction in 2025 would be 50% among females, in comparison
to 56% among males (Fig 5). Uncircumcised males will also benefit if such efficacy exists,
though indirectly and at lower levels. The reduction in HIV incidence rate in 2025 among
uncircumcised males in the population, regardless of circumcision status, would be 16% at 0%
efficacy in comparison with 36% at 46% efficacy (data not shown).
Limitations
Our results may depend on the type of mathematical model structure used and input parame-
ters incorporated in the model. The availability of precise and representative time-trend data
for HIV prevalence, baseline male circumcision prevalence, and demographic data such as
total population size and future projections is critical for the formulation and examination of
the modeled intervention scenarios. In the modeled intervention scenarios, we assumed a
fixed VMMC rate in all scenarios, which does not precisely capture the current VMMC scale-
up rate for Zambia. We assumed that exclusion or inclusion of HIV-positive males in VMMC
programs may change uptake among higher-risk males by as much as 20%. However, there are
no empirical data reporting how exactly uptake changes with exclusion or inclusion of HIV-
positive males. In the intervention scenarios tested here, we assumed different levels of efficacy
for male circumcision against male-to-female HIV transmission. Nonetheless, a conclusive
estimate of the size of this protective effect is still lacking.
Despite these potential limitations, we used an elaborate mathematical model structure (the
ASM model) that can capture the complexity of different effects of VMMC programs on HIV
dynamics (S1 Text) [38]. Among these complexities is the effect of VMMC intervention on
onward HIV transmission—that is the indirect effect of VMMC on females by reducing HIV
incidence among circumcised males. This model is an extension of earlier models that were
developed and refined over the years to study HIV epidemic dynamics in SSA [45, 67, 68]. We
conducted a multivariate uncertainty analysis on our model predictions to assess the impact of
changes in the structural, behavioral and biological parameters of the model. This analysis
affirmed the validity of our predictions (S3 Fig). Our model was parameterized by current
empirical epidemiological data on HIV infection in SSA, and particularly in Zambia, though
most of the biological data were from other SSA countries and they may not represent data
from Zambia if such data will become available. Although we used a fixed scale-up rate rather
than Zambia’s precise (variable) VMMC scale-up rate, our earlier modeling study showed that
the impact of the VMMC program using a variable VMMC scale-up rate was virtually similar
to that with a fixed rate [38].
Scale-up of other interventions such as ART or condom distribution may potentially
diminish the benefits of VMMC scale-up programs. However, our earlier modeling study
showed that even with an optimistic ART scale-up scenario, VMMC in an HIV hyper-endemic
setting such as Zambia will remain an impactful and effective intervention. Also, scale-up of
ART is not likely to change our predictions of the programmatic implications of including
HIV-positive males in VMMC programs, as our study focused on the relative differences in
VMMC effectiveness across scenarios rather than the absolute changes in VMMC
effectiveness.
In our model we did not explore other relevant components of VMMC efficiency such as
that of reduction in HIV testing costs that may shift the trade-offs in balance of a broad recruit-
ment strategy. Also, the implications of inclusion of HIV-positive males in VMMC programs
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was only assessed at a national level rather than at subregional and/or rural versus urban levels.
Nonetheless, an earlier modeling study indicated that geographical heterogeneities do not
have a considerable effect on the relative difference in VMMC effectiveness [38].
Furthermore, though we do not yet know the exact magnitude of the efficacy of male cir-
cumcision against male-to-female HIV transmission, a mounting body of evidence suggests
that the effect is sizable [19, 20, 65]. To accommodate a range of predictions in our study, we
assumed three different male circumcision efficacy levels. The results indicated that including
HIV-positive males at a rate proportional to their representation in the population (e.g. 12.6%
of those circumcised in 2010) is unlikely to undermine the effectiveness of VMMC programs
(Fig 4). We also conducted a sensitivity analysis that accommodates for higher HIV infectious-
ness among circumcised males who resume their sexual activity before the complete healing of
the circumcision wound (S4 Fig). The analysis indicated that resumption of sexual activity
during the healing period of the circumcision wound will only minimally reduce the effective-
ness of VMMC programs (compare results in S4 Fig with Fig 2), and only in the short term, as
has been shown in earlier modeling studies [7, 8, 20, 25, 34].
Conclusion
Improving the inclusivity of all males in VMMC programs is likely to enhance the programs’
effectiveness. Enhanced effectiveness would occur with moderate increases in the uptake of
VMMC among males at higher risk and/or if male circumcision has moderate efficacy against
male-to-female HIV transmission. In these circumstances, the one-time VMMC intervention
can reduce the HIV incidence rate within a population by as much as some lifelong ART pro-
grams do. The reduction in incidence rate among females under these conditions can also be
nearly as high as that among males.
In light of these results, VMMC programs may wish to attract males regardless of their will-
ingness to test for HIV and learn their HIV status. Program planners should not hesitate to
recruit VMMC clients among populations at higher risk for HIV infection for fear of inadver-
tently increasing participation by HIV-positive males. Indeed, we believe that restricting
recruitment in this way could affect the uptake of VMMC among both HIV-positive and -neg-
ative males, which would undermine a program’s overall impact. We believe that recruiting
clients regardless of their perceived HIV status or willingness to be tested could reduce stigma
and increase uptake of VMMC among higher-risk males, leading to more effective VMMC
programs. Better understanding of the factors that affect the uptake of VMMC among males
will allow programs to overcome the plausible lower uptake among higher-risk males while
maintaining their links to other HIV care and treatment services, such as HTC.
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